News|Articles|November 17, 2026

FDA Approves Adrabetadex for Infantile-Onset Niemann-Pick Type C

Fact checked by: Laura Joszt, MA
Listen
0:00 / 0:00

Key Takeaways

  • FDA requested data/documentation updates, triggering a major amendment and a 3-month PDUFA extension despite priority review and prior breakthrough therapy designation.
  • Orphan drug and rare pediatric disease designations were granted, reflecting high unmet need in infantile-onset NPC and potential eligibility for pediatric priority review voucher pathways.
SHOW MORE

FDA approved adrabetadex for infantile-onset Niemann-Pick disease type C after survival data showed 84% vs 42% 5-year survival with treatment.

Adrabetadex (VTS-270; Beren Therapeutics) was recently ___ by the FDA to treat infantile-onset Niemann-Pick disease type C (NPC).1

The first-in-class, disease-modifying approach is an investigational cyclodextrin therapy designed to increase intracellular cholesterol trafficking in patients with NPC.2

Adrabetadex’s Path Through FDA Review

The delayed decision came less than a year after Beren Therapeutics’ new drug application (NDA) was accepted for priority review in late February 2026. The original Prescription Drug User Fee Act (PDUFA) target action date was set for August 17, 2026.2 The delay stemmed from an FDA request for updates and clarifications to existing data and supporting documentation. The company’s response was classified as a major amendment to the filing, which extended the PDUFA target action date by 3 months, to November 17, 2026.3 The drug had received priority review status, which followed a breakthrough therapy designation announced in December 2025.2,4

Adrabetadex was also granted orphan drug and rare pediatric disease designations, further underscoring the treatment need within this disease.4

Understanding Infantile-Onset Niemann-Pick Disease Type C

NPC is a rare, autosomal recessive, severe, neurodegenerative disorder. Pathogenic variants in the NPC1 and NPC2 genes, with NPC1 accounting for about 95% of cases, lead to impaired cholesterol trafficking and thus neurological decline and premature death.2

Infantile-onset NPC refers to children who first experience neurological symptoms between the ages of 0 and 6 years. Onset before age 2 is associated with more rapid progression and poorer outcomes, with a mean survival of about 5.6 years, compared with about 13.4 years for onset between ages 2 to younger than 6 years.2,4

Survival Benefit Seen in WORLDSymposium Data

Earlier findings on the drug’s survival and disease progression benefits were presented at the 22nd Annual WORLDSymposium, held February 2-6, 2026, in San Diego, California.5 Eligible participants were pooled from the phase 2b/3 trial with open-label extension (VTS301: Parts A/B [NCT02534844] and Part C [NCT04958642, which included participants from Parts A/B and the phase 1/2a study, NCT01747135]) and from expanded access programs (EAPs; RUSH IND 119856, VTS-270-001, and the Canadian Special Access Program). In total, 72 adrabetadex-treated participants were matched with 119 external controls.5

The data showed adrabetadex was associated with a 71% lower risk of death compared with matched external controls (HR, 0.289; 95% CI, 0.141-0.593; P < .0001). The 5-year overall survival (OS) rate was 84% with adrabetadex vs 42% among external controls.5

Overall, infantile deaths were also lower in the adrabetadex group (17 [23.6%] vs 44 [61.2%]). The treatment also reduced the annual rate of disease progression by 43%, from 1.34 units/year before treatment to 0.76 units/year during treatment (difference, –0.58 units/year; 95% CI, –0.98 to –0.18; P = .0055).5

References

1.

2. Beren Therapeutics announces FDA acceptance of its new drug application for adrabetadex in infantile-onset Niemann-Pick disease type C. Beren Therapeutics. February 23, 2026. Accessed November 17, 2026. https://www.berentx.com/news/adrabetadex-nda-accepted-priority-review-npc/

3. FDA extends Beren’s rare disease review after info request, further stretching saga. Fierce Biotech. May 28, 2026. Accessed November 17, 2026. https://www.fiercebiotech.com/biotech/fda-extends-berens-rare-disease-review-after-info-request-further-stretching-saga

4. FDA grants breakthrough therapy designation to investigational drug adrabetadex for individuals with infantile-onset Niemann-Pick disease type C. Beren Therapeutics. December 9, 2025. Accessed November 17, 2026. https://www.berentx.com/news/adrabetadex-receives-breakthrough-designation-by-fda/

5. Berry-Kravis E, Keller LH, Jiao L, et al. Substantial survival benefit and slowing of disease progression with adrabetadex treatment in individuals with infantile-onset Niemann-Pick disease type C (NPC). Presented at: 22nd Annual WORLDSymposium; February 2-6, 2026; San Diego, CA. Poster LB-13.


Related to this article